Expression of plant-produced anti-PD-L1 antibody with anoikis sensitizing activity in human lung cancer cells via., suppression on epithelial-mesenchymal transition.
Thareeya PhetphoungAshwini MallaKaewta RattanapisitNuttapat PisuttinusartNaruechai DamrongyotKeerati JoyjamrasPithi ChanvorachoteTanapati PhakhamTossapon WongtangprasertRichard StrasserChatchai ChaothamWaranyoo PhoolcharoenPublished in: PloS one (2022)
Immune checkpoint antibodies in cancer treatment are receptor-ligand pairs that modulate cancer immunity. PD-1/PD-L1 pathway has emerged as one of the major targets in cancer immunotherapy. Atezolizumab, the first anti-PD-L1 antibody approved for the treatment of metastatic urothelial, non-small cell lung, small cell lung and triple-negative breast cancers, is produced in Chinese Hamster Ovary (CHO) cells with several limitations i.e., high-production costs, low-capacity yields, and contamination risks. Due to the rapid scalability and low production costs, the transient expression in Nicotiana benthamiana leaves was investigated by co-infiltration of Agrobacterium tumefaciens GV3101 cultures harboring the nucleic acid sequences encoding for Atezolizumab heavy chain and light chain in this study. The transient expression of Atezolizumab in transformed N. benthamiana accumulated up to 86.76 μg/g fresh leaf weight after 6 days of agroinfiltration (OD 600 nm: 0.4) with 1:1 ratio of heavy chain to light chain. The structural and functional characteristics of plant-produced Atezolizumab was compared with commercially available Tecentriq® from CHO cells with similar binding efficacies to PD-L1 receptor. The direct anti-cancer effect of plant-produced anti-PD-L1 was further performed in human lung metastatic cancer cells H460 cultured under detachment condition, demonstrating the activity of anti-PD-L1-antibody on sensitizing anoikis as well as the suppression on anti-apoptosis proteins (Bcl-2 and Mcl-1) and modulation of epithelial to mesenchymal regulating proteins (E-cadherin, N-cadherin, Snail and Slug). In conclusion, this study manifests plants as an alternative cost-effective platform for the production of functional monoclonal antibodies for use in cancer therapy.
Keyphrases
- epithelial mesenchymal transition
- poor prognosis
- cell cycle arrest
- induced apoptosis
- binding protein
- cancer therapy
- squamous cell carcinoma
- nucleic acid
- small cell lung cancer
- stem cells
- cell therapy
- endoplasmic reticulum stress
- risk assessment
- signaling pathway
- human health
- bone marrow
- climate change
- transcription factor
- high resolution
- cell wall
- atomic force microscopy
- cell migration
- lymph node metastasis
- subarachnoid hemorrhage